Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10286529 | 0.83 | NLRP3 (0.36) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL10286899 | 0.81 | RXRA (0.36) | KDM4EALDH1A1HPGDHSD17B10BRD4 | |
| SCHEMBL10286445 | 0.81 | BRD4 (0.37) | KDM4EALDH1A1HPGDHSD17B10BRD4 | |
| SCHEMBL10286636 | 0.76 | ALDH1A1 (0.39) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL527312 | 0.75 | UHRF1 (0.44) | KDM4EALDH1A1HPGDHSD17B10BRD4 | |
| SCHEMBL526208 | 0.74 | NOS3 (0.51) | KDM4EALDH1A1HPGDHSD17B10TDP1 | |
| SCHEMBL10286634 | 0.73 | SMN1; SMN2 (0.35) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL10270852 | 0.72 | KDM4E (0.37) | KDM4EALDH1A1HPGDHSD17B10BRD4 | |
| SCHEMBL10286588 | 0.72 | KDM4E (0.36) | KDM4EALDH1A1HPGDHSD17B10BRD4 | |
| SCHEMBL10286848 | 0.72 | UHRF1 (0.44) | KDM4EALDH1A1HPGDHSD17B10POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140162980-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140162980-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140162980-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2014-06-12 | — | — | US | disclosed |
| EP-2598487-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | Syngenta Participations AG (CH) | 2013-06-05 | — | — | EP | disclosed |
| EP-2588456-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | Syngenta Participations AG (CH) | 2013-05-08 | — | — | EP | disclosed |
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2012013754-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012013754-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012001040-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012001040-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | MSR1, DDT, MPO | KDM4E 1075/4885ALDH1A1 1110/4885HPGD 1600/4885 |
| US-20140162980-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | PRDX4, PRDX6, DDT | KDM4E 428/4885ALDH1A1 1961/4885HPGD 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.